International Phase III development, regulatory approval and commercialization of E2006 (Dayvigo) for insomnia
A drug development program for the orexin receptor antagonist E2006 (Dayvigo), involving international Phase III trials in insomnia and advancing toward regulatory approval and launch in countries including China.
Companies1How many companies write about this.
Threads1One company can carry more than one thread here.